Tirz Rx vs Wegovy: how tirzepatide stacks up

Last updated 2026-07-27

What's the actual difference between tirzepatide and Wegovy?

Wegovy is the brand name for semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. It was approved by the FDA in June 2021 for chronic weight management ^[1]. Tirzepatide is a different molecule entirely, made by Eli Lilly, and it activates two receptors instead of one: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Lilly sells it as Zepbound for weight loss (approved November 2023) and as Mounjaro for type 2 diabetes (approved May 2022) ^{[2] [3]}. The dual-receptor mechanism is the whole story here. GIP on its own doesn't do much for weight in humans, but combined with GLP-1 agonism it seems to amplify appetite suppression and improve insulin sensitivity more than GLP-1 alone. That's the working theory behind why tirzepatide has outperformed semaglutide in cross-trial comparisons so far. Both drugs are once-weekly subcutaneous injections. Both slow gastric emptying, blunt appetite, and improve blood sugar control. Both carry a boxed warning about thyroid C-cell tumors based on rodent studies, though neither has confirmed this risk in humans ^{[2] [4]}. The similarities mostly end at mechanism class.

Which one produces more weight loss, tirzepatide or Wegovy?

In their respective phase 3 trials, tirzepatide produced larger average weight loss than semaglutide, though these are separate studies in separate patient populations, not a direct head-to-head. In SURMOUNT-1 (NCT04184622), adults with obesity or overweight without diabetes lost an average of 20.9% of body weight on the 15 mg dose over 72 weeks, compared to 3.1% on placebo ^[5]. In STEP 1 (NCT03548935), semaglutide 2.4 mg produced 14.9% average weight loss over 68 weeks versus 2.4% on placebo ^[2]. A retrospective real-world cohort study published in JAMA Internal Medicine in 2024 compared tirzepatide and semaglutide users directly (not a randomized trial, but matched patient records). At 12 months, tirzepatide users were significantly more likely to achieve 15% or greater weight loss than semaglutide users ^[6]. This is the closest thing to an apples-to-apples comparison available right now, and it points the same direction as the separate trials. No randomized controlled trial has pitted tirzepatide directly against semaglutide for weight loss as of this writing. Until one exists, the honest answer is: tirzepatide beat semaglutide's numbers in separate trials and in one large observational cohort, but we don't have a gold-standard head-to-head yet.

How do the dosing schedules compare?

Both drugs use a slow titration to reduce nausea and GI side effects, but the schedules and max doses differ. | | Tirzepatide (Zepbound/Mounjaro) | Semaglutide (Wegovy) |

Branded tirzepatide vs compounded tirzepatide: what's the difference?

Branded Zepbound and Mounjaro are FDA-approved products manufactured by Eli Lilly under strict quality controls, with fixed doses and pen devices verified in clinical trials. Compounded tirzepatide is a different animal: it's prepared by a compounding pharmacy from bulk tirzepatide, and it does not go through the same FDA approval process as the branded drug. Compounding became legal and common during the FDA's official tirzepatide shortage, when 503A and 503B pharmacies were permitted to compound versions of a drug in short supply under federal law. The FDA removed tirzepatide from its shortage list in December 2024, which narrowed the legal basis for mass compounding, though litigation and enforcement details have kept shifting since ^[8]. Anyone considering compounded tirzepatide should get it through a provider-reviewed pathway that sources from a legitimate, inspected pharmacy, not a gray-market seller with no clinical oversight. This matters for practical reasons too. Compounded formulations aren't tested by the FDA for the exact same purity, potency, and stability standards as Zepbound, and dosing conventions can vary between compounding pharmacies. If you go this route, understanding how to reconstitute Tirz Rx correctly and knowing how to inject properly becomes your responsibility in a way it isn't with a pre-filled brand pen. Wegovy, notably, does not currently have a widely compounded generic-style equivalent in the same way tirzepatide has had, because semaglutide's shortage and compounding situation followed a different timeline and was also affected by the FDA removing it from the shortage list in early 2025.

What are the side effects, and are they different between the two drugs?

The side effect profiles overlap heavily because both drugs slow digestion the same basic way. Nausea, diarrhea, constipation, vomiting, and stomach pain are the most commonly reported adverse events in both drug families' trials ^{[2] [4]}. In SURMOUNT-1, nausea occurred in about 24-33% of tirzepatide-treated patients depending on dose, and diarrhea in about 15-17% ^[5]. In STEP 1, nausea occurred in 44% of semaglutide patients and vomiting in 24% ^[2]. Cross-trial percentages aren't a clean comparison because trial populations and reporting methods differ, but GI symptoms are clearly the dominant complaint for both drugs. Both drugs carry the same boxed warning: contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), based on thyroid C-cell tumors seen in rodent studies ^{[2] [4]}. It is not known whether this risk translates to humans, and no confirmed cases have been established in clinical trial data, but the FDA requires the warning regardless. Both drug labels also carry warnings about acute pancreatitis, gallbladder disease (including gallstones), acute kidney injury (often secondary to dehydration from GI side effects), and hypoglycemia risk when combined with insulin or sulfonylureas ^{[2] [4]}. Gallbladder-related events were reported in a small but real percentage of patients in both SURMOUNT-1 and STEP 1 trials, generally under 3%. None of this is minor; if you have a history of pancreatitis or gallbladder disease, that's a conversation to have with a prescriber before starting either drug, not after.

Does tirzepatide or Wegovy work better for type 2 diabetes?

For blood sugar control specifically, tirzepatide (as Mounjaro) has also outperformed semaglutide in a real head-to-head trial, which is more definitive than the weight-loss comparisons. SURPASS-2 (NCT03987919) directly compared tirzepatide to semaglutide 1 mg (not the higher 2.4 mg weight-loss dose) in adults with type 2 diabetes. At 40 weeks, tirzepatide at all three doses (5, 10, and 15 mg) produced significantly greater reductions in HbA1c than semaglutide 1 mg, and greater weight loss as well ^[9]. The study's published conclusion states that tirzepatide was "noninferior and superior" to semaglutide for HbA1c reduction at all three doses tested ^[9]. This is one of the few genuine head-to-head trials in this drug class, and it's a meaningfully stronger form of evidence than the cross-trial weight comparisons above. It's worth flagging that SURPASS-2 used semaglutide 1 mg, not the 2.4 mg dose approved for weight loss under the Wegovy brand. So this trial answers the diabetes question well but doesn't directly settle the weight-loss question at matched top doses.

How does the cost compare?

List prices for both branded drugs are high, and actual out-of-pocket cost depends heavily on insurance coverage, manufacturer savings programs, and whether a pharmacy benefit manager has the drug on formulary. Zepbound's list price is roughly $1,059.87 per month for a one-month supply of the maintenance dose, per Eli Lilly's published pricing information, though the company has also introduced lower cash-pay options through LillyDirect for certain doses and vial formats . Wegovy's list price runs similarly high, and Novo Nordisk has likewise introduced its own direct-to-consumer cash pricing programs (NovoCare) to compete on the self-pay segment . Compounded tirzepatide, when available legally, has generally run cheaper per month than either branded product's list price, which is a major reason patients have sought it out despite the tradeoffs in oversight described above. Prices vary by compounding pharmacy, dose, and region, and change often enough that any specific number quoted here would likely be stale within months, so check current pricing directly with a provider-reviewed source rather than relying on older cost claims.

Which drug is easier to get insurance coverage for?

Coverage for both drugs is inconsistent and depends on whether your plan considers weight loss or diabetes to be the indication. Mounjaro (diabetes) tends to get better insurance coverage than Zepbound (weight loss) because many commercial and Medicare plans still treat obesity treatment as an exclusion, despite it being FDA-approved. The same asymmetry applies to Ozempic (diabetes) versus Wegovy (weight loss), which are both semaglutide but marketed under different names for different indications. Medicare Part D, as of current CMS guidance, does not cover drugs prescribed solely for weight loss, though it can cover the same drug when prescribed for an FDA-approved indication like type 2 diabetes or, more recently, reduction of cardiovascular risk in patients with obesity and established cardiovascular disease. Coverage rules shift year to year, so checking your specific plan's formulary is the only reliable way to know what you'll actually pay.

Can you switch from Wegovy to tirzepatide, or vice versa?

People do switch between the two, usually because of cost, side effects, insurance formulary changes, or because they plateaued on one and want to try the other's mechanism. There's no FDA-published conversion chart between semaglutide and tirzepatide doses because they're structurally different drugs, not different strengths of the same molecule. In practice, prescribers generally restart tirzepatide at its own low starting dose (2.5 mg) rather than trying to "convert" a Wegovy dose numerically, since GI tolerance has to be rebuilt for the new drug regardless of what dose you'd reached on the old one. If you're planning a switch, that's a conversation for your prescriber, and understanding your Tirz Rx dosage plan and expected cycle length upfront helps set realistic expectations for the restart period.

Who should not take tirzepatide or Wegovy?

Neither drug should be used by anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, per both drugs' boxed warnings ^{[2] [4]}. Neither is approved for use in pregnancy; both labels recommend discontinuing before a planned pregnancy given the unknown effects on fetal development, and semaglutide's label specifically notes it should be stopped at least two months before a planned pregnancy due to its long half-life ^[4]. Patients with a history of pancreatitis, severe gastroparesis, or gallbladder disease need a careful risk conversation before starting either drug, since both increase the risk of these same complications. Neither drug has been studied in patients under 12 (Wegovy has a pediatric indication down to age 12 for weight management; Zepbound does not currently have a pediatric weight-loss indication) ^{[1] [3]}. Type 1 diabetics are not the intended population for either drug's diabetes indication, since neither is approved to treat type 1 diabetes. If you've had a serious allergic reaction to a previous GLP-1 or GIP agonist, that history alone is often reason enough for a prescriber to avoid the whole drug class rather than test another member of it.

How long do you need to stay on either drug to keep the weight off?

Both drugs are designed for long-term use, and the trial data on stopping either one tells a consistent story: weight tends to come back. A substudy of SURMOUNT-4 (NCT04660643) found that patients who stopped tirzepatide after a 36-week lead-in phase regained a substantial portion of lost weight over the next year, while those who continued kept losing . STEP 4 found a similar pattern with semaglutide: patients switched to placebo after 20 weeks regained on average about two-thirds of the weight they'd lost during the active treatment phase within the following year . Neither drug is a short course you take and stop. The practical implication is that anyone starting either treatment should think of it as a long-term commitment (months to years, not weeks), and should plan for how they'll maintain results if they ever do come off it, whether through continued lower-dose maintenance, lifestyle changes built during treatment, or a different long-term plan discussed with a prescriber.

Frequently asked questions

Is tirzepatide stronger than Wegovy?

In separate phase 3 trials, tirzepatide produced greater average weight loss (20.9% at 72 weeks in SURMOUNT-1) than semaglutide/Wegovy (14.9% at 68 weeks in STEP 1). A large observational cohort study also found tirzepatide users more likely to hit 15%+ weight loss. No randomized head-to-head trial for weight loss exists yet, so this isn't fully settled science.

Can I switch from Wegovy to tirzepatide?

Yes, people do this, usually for cost, side effects, or plateauing. There's no official dose conversion chart since they're different molecules. Prescribers typically restart tirzepatide at its lowest dose (2.5 mg) and re-titrate slowly, regardless of what dose you reached on Wegovy.

Is Zepbound the same as compounded tirzepatide?

No. Zepbound is Eli Lilly's FDA-approved, manufactured tirzepatide product in a pre-filled pen. Compounded tirzepatide is prepared by a compounding pharmacy from bulk drug substance and does not go through the same FDA approval, potency, or purity verification process as the branded product.

What's the difference between Mounjaro, Zepbound, and generic tirzepatide?

Mounjaro and Zepbound are the same molecule, tirzepatide, made by Eli Lilly under different brand names for different FDA-approved indications: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. There is no FDA-approved generic tirzepatide yet; compounded versions are not generics in the regulatory sense.

Does tirzepatide or Wegovy have worse side effects?

Both cause similar GI side effects (nausea, diarrhea, constipation, vomiting) as their most common complaints. Reported nausea rates run roughly 24-44% depending on the trial and dose, with wide variation by study design, so a clean head-to-head percentage comparison isn't reliable across separate trials.

Do tirzepatide and Wegovy both have a boxed warning?

Yes. Both drug labels carry an FDA boxed warning about thyroid C-cell tumors seen in rodent studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Human risk hasn't been confirmed in either case.

Which is cheaper, tirzepatide or Wegovy?

Both branded drugs (Zepbound, Wegovy) have list prices over $1,000 per month, though both manufacturers now offer direct cash-pay programs at lower prices for certain doses. Compounded tirzepatide has generally cost less than branded list price where legally available, but pricing shifts often and should be checked directly with a provider.

Is tirzepatide better for diabetes than Wegovy/semaglutide?

Based on the SURPASS-2 head-to-head trial, tirzepatide produced significantly greater HbA1c reduction than semaglutide 1 mg at all three tested doses over 40 weeks. This trial used the diabetes dose of semaglutide, not the 2.4 mg Wegovy weight-loss dose, so it answers the diabetes question specifically.

What happens if I stop taking tirzepatide or Wegovy?

Trial data for both drugs shows substantial weight regain after stopping. A SURMOUNT-4 substudy found patients who stopped tirzepatide regained much of the lost weight within a year, and STEP 4 found semaglutide patients regained about two-thirds of lost weight after switching to placebo.

Can I take tirzepatide and Wegovy at the same time?

No. There's no clinical reason or trial evidence supporting combined use of two GLP-1 class drugs simultaneously, and doing so would compound GI side effect risk without established benefit. Prescribers use one or the other, not both together.

Does insurance cover tirzepatide or Wegovy better?

Coverage depends on indication more than drug. Diabetes-indicated versions (Mounjaro) tend to get better coverage than weight-loss versions (Zepbound, Wegovy) because many insurance plans, including Medicare Part D, exclude weight-loss-only prescriptions. Check your specific plan's formulary since rules change yearly.

Is compounded tirzepatide legal right now?

The legal basis for mass compounding narrowed after the FDA removed tirzepatide from its drug shortage list in December 2024, since 503A/503B compounding exceptions are tied to shortage status. Sourcing through a provider-reviewed, properly licensed pharmacy pathway matters more than ever given the shifting regulatory landscape.

Sources

1. FDA, Zepbound prescribing information / approval: Zepbound (tirzepatide) dosing schedule, boxed warning, and approval details
2. FDA, Wegovy prescribing information: Wegovy boxed warning, contraindications, and side effect profile
3. NEJM, SURMOUNT-1 trial (NCT04184622): Tirzepatide 15 mg produced 20.9% average weight loss at 72 weeks vs 3.1% placebo
4. NEJM, STEP 1 trial (NCT03548935): Semaglutide 2.4 mg produced 14.9% average weight loss at 68 weeks vs 2.4% placebo
5. JAMA Internal Medicine, tirzepatide vs semaglutide real-world cohort study: Retrospective cohort study found tirzepatide users more likely to achieve 15%+ weight loss than semaglutide users at 12 months
6. NEJM, SURPASS-2 trial (NCT03987919): Tirzepatide was noninferior and superior to semaglutide 1 mg for HbA1c reduction at all three doses tested
7. Eli Lilly, Zepbound pricing / LillyDirect: Zepbound list price and LillyDirect cash-pay pricing options
8. JAMA, SURMOUNT-4 trial (NCT04660643): Patients who stopped tirzepatide after lead-in phase regained substantial weight over the following year versus those who continued
9. JAMA, STEP 4 trial: Semaglutide patients switched to placebo regained about two-thirds of lost weight within a year